SCHEMBL30665778

SCHEMBL30665778

CC(=O)c1ccc(CCC(C)(C)C)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.42
SLC6A2 P23975 4/20 0.42
SLC6A4 P31645 4/20 0.42
SLC6A3 Q01959 4/20 0.42
EPHX2 P34913 2/20 0.42
NR1H4 Q96RI1 2/20 0.42
PKM P14618 1/20 0.40
ESRRA P11474 1/20 0.40
HTT P42858 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADRB2 P07550 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.37
HSD17B1 P14061 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17831661 1.00 CYP2D6 (0.42) CYP2D6SLC6A2SLC6A4SLC6A3EPHX2
SCHEMBL22836993 0.87 PKM (0.44) CYP2D6SLC6A2SLC6A4SLC6A3PKM
SCHEMBL17891912 0.84 EPHX2 (0.36) CYP2D6SLC6A2SLC6A4SLC6A3EPHX2
SCHEMBL4810977 0.81 PKM (0.47) EPHX2NR1H4PKMHTTMEN1
SCHEMBL26655796 0.80 EPHX2 (0.35) CYP2D6SLC6A2SLC6A4SLC6A3EPHX2
SCHEMBL16728864 0.79 TAS1R3 (0.49) EPHX2NR1H4PKMHTTMEN1
SCHEMBL17891892 0.78 PDE3B (0.44) EPHX2PKMHTTMEN1MAPT
SCHEMBL24959800 0.77 EPHX2 (0.42) EPHX2NR1H4PKMESRRAHTT
SCHEMBL21796357 0.77 EPHX2 (0.32) CYP2D6SLC6A2SLC6A4SLC6A3EPHX2
SCHEMBL21796356 0.77 EPHX2 (0.32) CYP2D6SLC6A2SLC6A4SLC6A3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373932-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373932-A1 DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF REN, PKD2, ALPI CYP2D6 12/4885SLC6A2 134/4885SLC6A4 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.